Competitive Benchmarking Reports

Inform your targeted therapy commercialization strategy with Diaceutics’ competitive benchmarking reports
March 24th, 2016
Pharma Readiness for Personalized Medicine Summary Report 2016

This report is a quantitative and qualitative assessment of pharma readiness to operate in a personalized medicine marketplace. It is a summary update to the 2015 Pharma Readiness for Personalized Medicine Report which examined how prepared pharmaceutical companies are for the emerging personalized medicine business model. This report specifically examines the revenue achievements and business ...

January 15th, 2016
Personalized Healthcare Brand Index Surveillance; Pharma Communication Trends for Companion Testing

This report is a unique study of the communication styles pharma uses for targeted therapy. The goal of this report was to determine who is educating about personalized healthcare in connection with therapy branding (initially in oncology) and to understand how the testing narrative around a brand is shaping current and evolving brand strategies. It’s not concerned with right or wrong but abo...

December 1st, 2015
Pharma Readiness for Personalized Medicine 2010-2015

This Diaceutics benchmark report is an essential examination of the current pharmaceutical industry and its readiness to operate in a personalized medicine marketplace. It examines how ‘ready’ the industry is to translate and capitalize on new discoveries in biomarkers, furthering debate on the industry’s role in developing personalized medicine solutions. It points to the dominant oncolo...

Latest Blogs

Blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients?
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.

Publications

August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
August 29th, 2017
Companion diagnostics driving new model for pharma-Dx partnerships
With a growing number of approvals for companion diagnostics, the pharmaceutical industry is taking keen interest in testing uptake and thinking about steps it can take to further drive testing.

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
March 24th, 2016
Pharma Readiness for Personalized Medicine Summary Report 2016

This report is a quantitative and qualitative assessment of pharma readiness to operate in a personalized medicine marketplace. It is a summary update to the 2015 Pharma Readiness for Personalized Medicine Report which examined how prepared pharmaceutical companies are for the emerging personalized medicine business model. This report specifically examines the revenue achievements and business ...

January 15th, 2016
Personalized Healthcare Brand Index Surveillance; Pharma Communication Trends for Companion Testing

This report is a unique study of the communication styles pharma uses for targeted therapy. The goal of this report was to determine who is educating about personalized healthcare in connection with therapy branding (initially in oncology) and to understand how the testing narrative around a brand is shaping current and evolving brand strategies. It’s not concerned with right or wrong but abo...

December 1st, 2015
Pharma Readiness for Personalized Medicine 2010-2015

This Diaceutics benchmark report is an essential examination of the current pharmaceutical industry and its readiness to operate in a personalized medicine marketplace. It examines how ‘ready’ the industry is to translate and capitalize on new discoveries in biomarkers, furthering debate on the industry’s role in developing personalized medicine solutions. It points to the dominant oncolo...

March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017

This report asks which pharma companies are ready for diagnostic integration and draws on benchmarking and financial risk assessment. Its analyses of 23 companies, plus therapies on the market and in the pipeline, provide a 360° view of diagnostic-dependent therapy assets. It features big data and lab partnerships alongside therapy/diagnostic partnerships to reflect the evolution of precisio...

March 24th, 2016
Pharma Readiness for Personalized Medicine Summary Report 2016

This report is a quantitative and qualitative assessment of pharma readiness to operate in a personalized medicine marketplace. It is a summary update to the 2015 Pharma Readiness for Personalized Medicine Report which examined how prepared pharmaceutical companies are for the emerging personalized medicine business model. This report specifically examines the revenue achievements and business ...

January 15th, 2016
Personalized Healthcare Brand Index Surveillance; Pharma Communication Trends for Companion Testing

This report is a unique study of the communication styles pharma uses for targeted therapy. The goal of this report was to determine who is educating about personalized healthcare in connection with therapy branding (initially in oncology) and to understand how the testing narrative around a brand is shaping current and evolving brand strategies. It’s not concerned with right or wrong but abo...

December 1st, 2015
Pharma Readiness for Personalized Medicine 2010-2015

This Diaceutics benchmark report is an essential examination of the current pharmaceutical industry and its readiness to operate in a personalized medicine marketplace. It examines how ‘ready’ the industry is to translate and capitalize on new discoveries in biomarkers, furthering debate on the industry’s role in developing personalized medicine solutions. It points to the dominant oncolo...

Blogs

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients?
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.

Publications

August 3rd, 2018
A Way Forward: Leveraging Advanced Diagnostic Testing to Unlock the Value of Precision Medicine
Read about how advanced diagnostic testing, ensuring that right patient gets the right therapy, at the right time, particularly with respect to therapies where the test result determines whether or not the therapy should be used (precision medicin...
August 29th, 2017
Companion diagnostics driving new model for pharma-Dx partnerships
With a growing number of approvals for companion diagnostics, the pharmaceutical industry is taking keen interest in testing uptake and thinking about steps it can take to further drive testing.

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...